Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruby F Meredith

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 9, 2005
Blood-based red marrow dosimetry: where's the beef?Jeffry A Siegel, Richard B Sparks, Robert M Sharkey, et al.
Advances in Radiation Oncology|July 26, 2017
A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastasesJohn B Fiveash, Waleed O Arafat, George E Naoum, et al.
American Journal of Clinical Oncology|September 1, 2007
Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 TrialDouglas P Calvin, M E Hammond, Thomas F Pajak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 18, 2008
MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapyBarry W Wessels, Mark W Konijnenberg, Roger G Dale, et al.
Journal of Pain and Symptom Management|July 18, 2009
Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapyBarbara A Murphy, Jennifer L Beaumont, John Isitt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancerRonald D Alvarez, Warner K Huh, M B Khazaeli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 17, 2013
MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applicationsYuni K Dewaraja, Michael Ljungberg, Alan J Green, et al.
Bone Marrow Transplantation|May 6, 2018
Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplantAyman Saad, Alankrita Taneja, Antonio Di Stasi, et al.
Blood|March 5, 2004
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaAndres Forero, Paul L Weiden, Julie M Vose, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2010
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapyGeorge Sgouros, John C Roeske, Michael R McDevitt, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 9, 2005
Blood-based red marrow dosimetry: where's the beef?Jeffry A Siegel, Richard B Sparks, Robert M Sharkey, et al.
Advances in Radiation Oncology|July 26, 2017
A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastasesJohn B Fiveash, Waleed O Arafat, George E Naoum, et al.
American Journal of Clinical Oncology|September 1, 2007
Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 TrialDouglas P Calvin, M E Hammond, Thomas F Pajak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 18, 2008
MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapyBarry W Wessels, Mark W Konijnenberg, Roger G Dale, et al.
Journal of Pain and Symptom Management|July 18, 2009
Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapyBarbara A Murphy, Jennifer L Beaumont, John Isitt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancerRonald D Alvarez, Warner K Huh, M B Khazaeli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 17, 2013
MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applicationsYuni K Dewaraja, Michael Ljungberg, Alan J Green, et al.
Bone Marrow Transplantation|May 6, 2018
Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplantAyman Saad, Alankrita Taneja, Antonio Di Stasi, et al.
Blood|March 5, 2004
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaAndres Forero, Paul L Weiden, Julie M Vose, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2010
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapyGeorge Sgouros, John C Roeske, Michael R McDevitt, et al.
Pageof 6